Based on the Bio-Techne Corp stock forecast from 3 analysts, the average analyst target price for Bio-Techne Corp is USD 84.33 over the next 12 months. Bio-Techne Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bio-Techne Corp is Slightly Bullish , which is based on 11 positive signals and 7 negative signals. At the last closing, Bio-Techne Corp’s stock price was USD 71.05. Bio-Techne Corp’s stock price has changed by -2.05% over the past week, +0.98% over the past month and +11.75% over the last year.
No recent analyst target price found for Bio-Techne Corp
No recent average analyst rating found for Bio-Techne Corp
Company Overview Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota. Read Less
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnost...Read More
Frequently Asked Questions About Bio-Techne Corp (TECH) Stock
Based on ratings from 3 analysts Bio-Techne Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and 1 hold ratings.
TECH stock's dividend yield is 0.42%.
Our analysis grades TECH stock's dividend yield at F. This means that TECH stock's dividend yield is above 14% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TECH may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for TECH is USD 84.33 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 70.
TECH stock's Price/Earning ratio is 79.27.
Our analysis grades TECH stock's Price / Earning ratio at F. This means that TECH stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TECH may be a overvalued for its sector.
The last closing price of TECH's stock was USD 71.05.
The most recent market capitalization for TECH is USD 11.95B.
Based on targets from 3 analysts, the average taret price for TECH is projected at USD 84.33 over the next 12 months.
This means that TECH's stock price may go up by +18.70% over the next 12 months.
We can't find any ETFs which contains Bio-Techne Corp's stock.
As per our most recent records Bio-Techne Corp has 3,100 Employees.
Bio-Techne Corp's registered address is 614 McKinley Place N.E., Minneapolis, MN, United States, 55413.
You can get more information about it from Bio-Techne Corp's website at https://www.bio-techne.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bio-Techne Corp (TECH) Stock
Based on ratings from 3 analysts Bio-Techne Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and 1 hold ratings.
TECH stock's dividend yield is 0.42%.
Our analysis grades TECH stock's dividend yield at F. This means that TECH stock's dividend yield is above 14% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TECH may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for TECH is USD 84.33 over the next 12 months. The maximum analyst target price is USD 95 while the minimum anlayst target price is USD 70.
TECH stock's Price/Earning ratio is 79.27.
Our analysis grades TECH stock's Price / Earning ratio at F. This means that TECH stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TECH may be a overvalued for its sector.
The last closing price of TECH's stock was USD 71.05.
The most recent market capitalization for TECH is USD 11.95B.
Based on targets from 3 analysts, the average taret price for TECH is projected at USD 84.33 over the next 12 months.
This means that TECH's stock price may go up by +18.70% over the next 12 months.
We can't find any ETFs which contains Bio-Techne Corp's stock.
As per our most recent records Bio-Techne Corp has 3,100 Employees.
Bio-Techne Corp's registered address is 614 McKinley Place N.E., Minneapolis, MN, United States, 55413.
You can get more information about it from Bio-Techne Corp's website at https://www.bio-techne.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TECH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
